Bradley J. Bolzon PhD

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Bradley J. Bolzon PhD

Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Common Stock
Shares / value
6,799,115
Estimated value
$129,183,185
Report date
28 Jun 2021
Price
$19.00
Ownership
By Versant Venture Capital VI, L.P.
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Common Stock
Shares / value
2,097,938
Estimated value
$39,860,822
Report date
28 Jun 2021
Price
$19.00
Ownership
By Versant Vantage I, L.P.
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
47,132
Estimated value
Report date
23 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Black Diamond Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
15,000
Estimated value
Report date
18 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

CRISPR Therapeutics AG

Security class
Stock Option (Right to Buy)
Shares / value
12,000
Estimated value
Report date
09 Jun 2022
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series A convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
Ownership
By Versant Capital VI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series B convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
$2.00
Ownership
By Versant Capital VI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series B convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
$2.00
Ownership
By Versant Vantage I, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Monte Rosa Therapeutics, Inc.

Security class
Series C convertible preferred stock
Shares / value
0
Estimated value
Report date
28 Jun 2021
Price
Ownership
By Versant Vantage I, L.P.
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Bradley J. Bolzon PhD

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .